Division of Nephrology, Department of Internal Medicine, School of Medicine, Mersin University, 33079 Mersin, Turkey.
Clin Chem Lab Med. 2013 Apr;51(4):889-95. doi: 10.1515/cclm-2012-0657.
Cancer biomarkers (CBs) can be used in early detection of several cancers as well as in detection of recurrence and following response to treatment. We aimed to investigate the levels of CBs in proteinuric patients with primary glomerular disease (PGD) and diabetes mellitus, and compare them with healthy controls.
One hundred and two patients with untreated PGD, 62 proteinuric patients with diabetic nephropathy, and 84 healthy controls were enrolled. Levels of cancer antigen 125 (CA 125), cancer antigen 15-3 (CA 15-3), carcinoembriogenic antigen (CEA), α-fetoprotein (AFP), total prostate specific antigen (TPSA), free prostate specific antigen (FPSA) and carbohydrate antigen 19-9 (CA 19-9) were measured.
Compared to healthy controls, levels of CA 125, CA 15-3 and CA 19-9 were higher in patients with PGD and diabetic patients (all p<0.05), while levels of TPSA, FPSA, AFP and CEA were lower (all p<0.05). There was no correlation between levels of cancer biomarkers and serum fibrinogen and serum amyloid A protein levels (all p>0.05). Both urinary protein excretion rate and serum albumin levels were correlated with all CBs (all p<0.05).
CBs levels seem to be changed in different proteinuric patients. This condition should be kept in mind when evaluating CBs levels in proteinuric patients.
癌症标志物（CBs）可用于早期发现多种癌症，以及检测复发和治疗反应。我们旨在研究原发性肾小球疾病（PGD）和糖尿病合并蛋白尿患者的 CBs 水平，并与健康对照组进行比较。
纳入 102 例未经治疗的 PGD 患者、62 例糖尿病肾病合并蛋白尿患者和 84 例健康对照组。测定 CA125、CA15-3、CEA、AFP、总前列腺特异抗原（TPSA）、游离前列腺特异抗原（FPSA）和 CA19-9 的水平。
与健康对照组相比，PGD 患者和糖尿病患者的 CA125、CA15-3 和 CA19-9 水平均升高（均 P<0.05），而 TPSA、FPSA、AFP 和 CEA 水平均降低（均 P<0.05）。CBs 水平与血清纤维蛋白原和血清淀粉样蛋白 A 蛋白水平无相关性（均 P>0.05）。尿蛋白排泄率和血清白蛋白水平与所有 CBs 均相关（均 P<0.05）。
不同蛋白尿患者的 CBs 水平似乎发生了变化。在评估蛋白尿患者的 CBs 水平时应考虑到这一情况。
